



Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Correction to: *Nature Medicine*
<https://doi.org/10.1038/s41591-023-02427-z>,
published online 24 June 2023.

<https://doi.org/10.1038/s41591-024-02890-2>

Published online: 04 March 2024

 Check for updates

Deepak L. Bhatt¹, Harold E. Bays, Michael Miller, James E. Cain III, Katarzyna Wasilewska, Nabil S. Andrawis, Teresa Parli², Shibao Feng, Lulu Sterling, Leo Tseng, Cynthia L. Hartsfield, Germaine D. Agollah, Hank Mansbach, John J. P. Kastelein & ENTRIGUE Principal Investigators*

In the version of the article initially published, there were errors in Fig. 3d. The panel has now been corrected in the HTML and PDF versions of the article, and the original and revised versions can be seen below as Fig. 1.

*A list of members and their affiliations appears in the Supplementary Information.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

Corrections & amendments




Fig. 1 | Original and revised Fig. 3d.